RWJ 50271

Research use only, not for human use.

RWJ 50271 is a selective lymphocyte function-associated antigen-1/intercellular adhesion molecule-1(LFA-1/ICAM-1) interaction inhibitor( IC50 of 5.0 μM in HL60 cells).

RWJ 50271 is a selective lymphocyte function-associated antigen-1/intercellular adhesion molecule-1(LFA-1/ICAM-1) interaction inhibitor( IC50 of 5.0 μM in HL60 cells).

RWJ 50271 inhibits adhesion of peripheral blood lymphocytes to plastic immobilized SICAM-1.RWJ 50271 inhibits both human and murine NK activity (IC50=5.0 μM) in an LFA-1/ICAM-1-dependent natural killer [NK] cytotoxicity assay.RWJ 50271 does not inhibit Mac-1/ICAM-1, E-selectidsialyl Lewis X or VLA-4/VCAM-1-mediated cell adhesion up to 20 μM concentrations.RWJ 50271 does not alter the LFA-1 expression levels on HL60 cells.RWJ 50271 inhibits adhesion of peripheral blood lymphocytes to plastic immobilized SICAM-1.RWJ 50271 does not exhibit any toxic activity up to 100 μM concentrations.

RWJ 50271 (50 mg/kg; p.o.) is effective in animal model of inflammation. Animal Model:Mice, the delayed-type hypersensitivity [DTH] reaction modelDosage:50 mg/kg Administration:Oral administration Result:Significantly reduced foot pad swelling (>50%) 48 h after the challenge.

——

Cell Cycle/DNA Damage

Integrin

LFA-1/ICAM-1

——

——

162112-37-0

410.41

C18H17F3N4O2S

>98% (HPLC)

DMSO:230 mg/mL?(487.32 mM), Need ultrasonic

Cc1c(cnn1-c1nc(cs1)-c1cccc(c1)C(F)(F)F)C(=O)NCCCO

——

(-20℃)

With Ice Pack

≥ 2 years